GE Healthcare Korea this week launched its new Clariscan macrocyclic gadolinium-based contrast agent (GBCA) for MRI scans in South Korea.
Clariscan is designed to visualize abnormalities in the brain, spine, and related tissue. GE first introduced Clariscan in March at ECR 2018 in Vienna. The company plans to introduce the new contrast agent to the rest of Europe and other parts of the world this year.
GE Healthcare Korea also this month installed its PETtrace 880 cyclotron and PET radiopharmacy suite at the Korea Institute of Radiological & Medical Sciences (KIRAMS).
PETtrace 880 is designed for both clinical and research applications and will be used for cancer diagnosis and treatment at KIRAMS' research center, which currently is under construction. The installation marks the 400th cyclotron production facility under the GE name.
